Management of alopecia areata by Harries, M J et al.
Management of alopecia areata
M J Harries clinical research fellow
1, J Sun post-doctoral fellow
2 associate professor of dermatology
3,
R Paus professor of dermatology
1 4, L E King Jr professor of medicine (dermatology)
5
1Epithelial Sciences, School of Translational Medicine, University of Manchester, Manchester;
2Jackson Laboratory, Bar Harbor, ME, USA;
3Department
of Dermatology, China-Japan Union Hospital of JiLin University, Chang Chun, People’s Republic of China;
4Department of Dermatology, University
of Lübeck, D-23538 Lübeck, Germany;
5Skin Disease Research Centre, Division of Dermatology, Vanderbilt Medical Center, Nashville, TN, USA
Alopeciaareataisacommonconditioncharacterisedbysudden
onset of patchy hair loss without signs of skin inflammation or
scarring. It accounts for about 2% of new referrals for
dermatology in the UK and United States and has an estimated
lifetime risk of 1.7%.
1 Data from the National Health and
Nutrition Examination Survey indicated a prevalence of 0.15%
in the population of the United States.
w1 The extent of hair loss
can vary greatly, ranging from a single coin sized patch to very
extensive alopecia involving the entire scalp and the rest of the
body. The condition is unpredictable; spontaneous regrowth of
hair can occur at any time during its course with the possibility
of subsequent relapse. Alopecia areata is particularly difficult
to manage and most of the available therapeutic options are
unsatisfactory. It is a psychologically distressing disease and
doctors should provide patients with realistic advice about
treatments and their effectiveness.
Althoughseveralmedicaltreatmentshavebeenreportedforthe
condition, the evidence is quite difficult to interpret because of
differingstudymethods,non-homogeneouspatientpopulations,
variability in outcome measures, and failure to control for
spontaneous regrowth. A recent Cochrane review concluded
that “there is no good trial evidence that any treatment provides
long-term benefit to patients with alopecia areata.”
2 However,
this review did not take into account studies using the “half
head” treatment method, in which only half the scalp is treated
until unilateral regrowth of hair is observed (fig 1⇓). This
method is regarded by hair specialists as a robust way to
differentiate treatment response from spontaneous regrowth.
w2
We aimed to review evidence for the management of alopecia
areatainabalancedwayanddiscusswhichtreatmentsmayhelp
patients.Wealsodiscusspotentiallyinterestingnewtreatments
that require further investigation.
Who gets alopecia areata?
Fortytofiftypercentofpatientsdevelopalopeciaareatabefore
age 21 years, while 20% develop it after the age of 40. Men and
women are affected equally, and there is no well defined racial
preponderance. Around 20% of patients have a positive family
history for the disease.
3
What are the characteristic clinical
features of alopecia areata and how is it
classified?
Alopeciaareatamostfrequentlypresentsasasingleroundpatch
or multiple patches of hair loss that may coalesce into larger
areas of alopecia (fig 2⇓). Complete loss of terminal hairs from
theentirescalp(alopeciatotalis)orthescalpandbody(alopecia
universalis) can sometimes develop, as may a band-like pattern
of hair loss at the occipital scalp margin (ophiasis). Although
the scalp is the most common site, any hair bearing skin may
be affected. The involved skin looks normal apart from being
devoid of hair. The extent and location of alopecia can vary
greatly between patients and within individuals over time. A
pathognomonic sign is the “exclamation mark” hair—this term
describesabrokenhairthatisthickertowardsthedistalendand
thinner at the base, usually found at the edge of an active area
of hair loss (fig 2). Nail changes such as pitting are seen in
around 10% of patients.
3w3
The characteristic histological feature is a variably dense
lymphocytic infiltrate around the growing hair bulb. Hairs are
prematurely converted from the growth (anagen) to regression
phase(catagen)withongoinginhibitionresultingindystrophic,
miniaturised hairs.
w4 Importantly, follicles are not destroyed by
this inflammatory process, so hair can potentially regrow even
after many years. Box 1 lists possible differential diagnoses.
What causes alopecia areata?
Alopecia areata is a T cell dependent autoimmune disease that
is specific to the skin. It occurs in genetically susceptible
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Clinical Review
CLINICAL REVIEWSummary points
• Alopecia areata is a common cause of patchy hair loss in adults and children and can greatly affect quality of life.
• Spontaneous hair regrowth occurs within a year in over half of people with patchy disease.
• Objective assessment of treatment efficacy is very difficult due to the high but unpredictable rate of spontaneous remission.
• First line treatments are topical immunotherapy for extensive disease and intralesional corticosteroids for localised patchy hair loss.
• Half-head treatment regimens can be used to control for spontaneous hair regrowth in trials of topical treatment.
• Standardised trial methods with clinically meaningful endpoints should be adopted by all future studies to help identify optimal treatments
Sources and selection criteria
We used our knowledge of the medical literature, treatment guidelines from national organisations (including the National Alopecia Areata
Foundation, United States), the Cochrane Library, and searches of PubMed (search term: alopecia areata).
Box 1 Differential diagnoses
• Tinea capitis should be suspected in any case of patchy hair loss when evidence of scalp inflammation exists, particularly in children.
Fungal microscopy and culture should be performed.
• Trichotillomania is where hairs are removed by the patient. The hair loss is usually incomplete with multiple broken hairs of varying
length. Younger children often grow out of this disorder but in older children and adults it may signify more marked psychological
problems.
• Cicatricial (scarring) alopecias are uncommon inflammatory disorders that target and destroy the hair follicle, resulting in permanent
alopecia. They are characterised clinically by loss of visible follicular ostia. Scalp biopsy is often diagnostic.
w36
individualswhendefectsoccurinlocalisedimmunosuppressive
mechanisms that normally “hide” defined tissue compartments
from immune attack (termed “immune privilege”) in the
proximal anagen hair follicle. These mechanisms include
reduced expression of major histocompatibility complex class
I and upregulation of locally generated immunosuppressants.
In mice, alopecia areata lesions can be induced by the transfer
of activated T-cells but not by serum, suggesting that
autoreactive T-cells rather than autoantibodies play a part in
disease pathogenesis.
4 Large case reviews have shown that
alopeciaareataisassociatedwithseveraldifferentautoimmune
conditions, particularly thyroid disease and vitiligo.
w3 w5
How is alopecia areata diagnosed?
Alopecia areata is generally diagnosed clinically; although
fungal cultures (to identify dermatophyte infections that can
mimic annular lesions of alopecia areata) and scalp biopsy (to
identify diagnostic histological features of alopecia areata or
exclude other hair loss conditions) may help in difficult cases.
A history of patchy hair loss that has regrown is highly
indicative of alopecia areata. Routine screening for associated
autoimmune conditions is not currently recommended by the
British Association of Dermatologists.
3
What is the natural history of untreated
alopecia areata?
At least 50% of patients with patchy disease lasting less than a
year will experience spontaneous remission, although further
episodesarecommon.
w6Afollow-upstudyidentifiedremission
rates of 34-50% within a year in patients who had reached
secondarycare;however,sustainedremissionisrareinpatients
with extensive disease and reportedly occurs in less than 10%
of cases.
3 5 6 The high, but unpredictable, rate of spontaneous
remission means that it is difficult to objectively assess the
efficacy of treatment.
Most patients (86-100%) will develop further episodes of
alopecia areata and data from large case series suggest that
around 30% of patients with patchy disease will eventually
progresstocompletehairloss.
5 w3Themostimportantprognostic
factors are the extent and pattern of disease. Alopecia totalis,
alopecia universalis, and ophiasis have the worst outcomes,
withlowerratesofspontaneousremissionandpoorerresponses
to therapy than other presentations. Onset before puberty,
co-existing atopy, associated autoimmune diseases, nail
dystrophy, long disease duration, and a positive family history
are risk factors for more severe disease.
3
How is alopecia areata managed?
General advice
Ifeyelashesarelost,glassesshouldbewornoutdoorstoprotect
the eyes from airborne particles. Exposed scalp skin should be
protected from sun damage with a hat or sunscreen. Many
patients find wigs or scalp cosmetics useful ways to cope with
their hair loss, and dermatography (tattooing) of eyebrows can
produce good cosmetic results. The psychological effect of
alopecia areata should be explored with the patient (box 2).
Sources of information and support, such as patient support
groups (see Additional Resources) can be invaluable.
To treat or not to treat?
Since as many as half of patients will spontaneously regrow
hair within a year,
3 6 opting not to treat is perfectly reasonable
for many patients. Discussion of poor prognostic factors and
the relapsing nature of the condition with patients is important
to help them to make up their mind.
Treatment options supported by controlled
clinical trials or half-head studies
Intralesional corticosteroids and topical immunotherapy (fig
1⇓) are the only current treatments that are generally agreed by
hair experts to be effective. They are thus recommended by
widely accepted guidelines as first line treatment options for
alopecia areata.
3 w7 w8
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CLINICAL REVIEWBox 2 Psychological toll of alopecia areata
The individual level of psychosocial distress caused by alopecia areata is often underestimated. Significantly impaired quality of life (measured
using dermatology life quality index
w33) along with increased anxiety and depression scores and low self esteem are common findings in
patients with the condition.
w34 Patient support networks (see www.naaf.org) and psychological therapies may help patients to develop positive
coping strategies and improve quality of life.
w35 The doctor should direct the patient to such non-medical supportive services.
Intralesional corticosteroids
No studies of intralesional corticosteroids fulfilled the recent
Cochranereview’scriteriaforinclusion.
2However,practitioners
have frequently observed that a tuft of terminal hairs grows at
thesiteofcorticosteroidinjectionandthisobservationhasbeen
considered a treatment response.
7 8 Prospective studies have
shown that intradermal injections of corticosteroid, usually in
the form of triamcinolone acetonide (5-10 mg/ml) used every
two to six weeks, stimulate localised regrowth at 60-67% of
injection sites.
7-9 Side effects include pain, localised atrophy,
and skin depigmentation. Textbooks and national guidelines
fromtheBritishAssociationofDermatologistsrecommendthis
approach as first line therapy for localised patchy disease,
3 w8
althoughrecentlythistreatmenthasalsobeensuccessfullyused
inextensivedisease(>50%scalparea)withareportedresponse
rate of 60%.
10
Topical immunotherapy
Contact immunotherapy, usually with
2,3-diphenylcyclopropenone(DPCP)orsquaricaciddibutylester
(SADBE), has been used in the treatment of extensive alopecia
areataforover30years.
w9Theobjectiveoftreatmentistoinduce
a low grade allergic contact dermatitis by initially sensitising
the patient, and then applying very weak concentrations of the
compound directly to the scalp once a week (web appendix).
Although no randomised controlled trials have evaluated the
effectiveness of topical immunotherapy in alopecia areata,
2
observationalstudieshaveusedthehalf-headmethodtocontrol
for spontaneous regrowth of hair (fig 1).
A comprehensive review of published topical immunotherapy
studies (SABDE=13 trials; DPCP=17 trials) found little
difference between the two agents. A weighted analysis found
that 58% patients across all the studies achieved at least 30%
regrowth, although relapse rates were high and increased with
longer follow-up periods.
11 The largest reported series (n=148)
of DPCP treatment found cosmetically acceptable regrowth in
17% of patients with alopecia totalis or universalis, 60% of
those with 75-99% hair loss, 88% with 50-74% hair loss, and
100% of patients with less than 50% hair loss.
12 DPCP has also
beenwidelyusedtotreatchildrenwithextensivealopeciaareata,
with rates of cosmetically acceptable regrowth of 27-33%.
w10
w11 Those with a long disease duration or extensive scalp
involvementrespondlesswell.
11Interestingly,inlimiteddisease
(<40% hair loss) there was no difference in treatment response
comparedwithplacebo,reflectingthehighratesofspontaneous
remission in patchy disease. Thus, topical immunotherapy
should be reserved for extensive disease only.
w12
Topical corticosteroids
Topical corticosteroids are widely used, although reports of
efficacyareconflicting.
2Arandomisedcontrolledtrialof0.25%
dexamethasone cream versus placebo over 12 weeks (n=70)
foundnostatisticallysignificantdifferenceinregrowthbetween
the groups.
13 A half-head comparison of 0.05% clobetasol
proprionate foam versus placebo (n=34) found over 50%
regrowth in seven of 34 patients in the active group compared
with one of 34 with placebo, but no formal statistical analyses
were performed.
14 Betamethasone valerate foam was
significantly more effective at regrowing hair in patchy disease
compared with betamethasone diproprionate lotion, although
an effect of the vehicle (the base compound in which the active
drug is mixed) could not be excluded.
15 In a small half-head
study of 28 patients with alopecia totalis or universalis who
usedclobetasolproprionateointmentunderpolytheneocclusion
daily for six months, eight (29%) had cosmetically acceptable
regrowth, although three of these subsequently relapsed and
failed to respond to re-treatment. Painful folliculitis was a
common side effect.
16 A double blind half-head placebo
controlledstudy(n=13)compared0.2%fluocinoloneacetonide
cream twice a day (under occlusion at night) with base vehicle
and showed unilateral regrowth in 54% in the treatment arm
compared with 0% in the vehicle group.
17
Therefore,potenttopicalcorticosteroids,asafoamformulation
or non-foam product under occlusion, seem beneficial in some
patients even when disease is extensive. Reassuringly, no
evidenceofsystemicabsorptionwasnotedinadultswhotreated
the whole scalp with super-potent steroids under occlusion for
six months.
16 The efficacy of weaker preparations and the
systemic effects of corticosteroids under occlusion in children
have not yet been addressed.
Systemic corticosteroids
Only one study of systemic corticosteroids in alopecia areata
has used a placebo controlled design.
18 A weekly single oral
dose of prednisolone (200 mg) was compared with placebo in
43 patients with “extensive” disease (>40% hair loss). After
three months, eight of 23 patients using prednisolone had
substantial(>31%)regrowthcomparedwithnoneintheplacebo
group (p<0.03; confidence intervals not supplied). However,
relapse was seen in 25% of responders within three months.
Uncontrolledstudiesofpulsedoralorintravenouscorticosteroid
regimens have also showed benefit. An “excellent” (>75%)
regrowth response was observed in 44-66% patients after six
months of treatment with 5 mg oral dexamethasone (or
betamethasone) on two consecutive days a week.
19 20 A review
of all published reports of the use of high dose intravenous
corticosteroids (218 patients) found that 68% achieved greater
than 50% regrowth of hair in multifocal alopecia areata, 30%
regrowthinophiasis,and23%inalopeciatotalisanduniversalis,
althoughasmanyasathirdofrespondersrelapsedwithinayear
and the number of relapses increased with time.
21 Interestingly,
topicalapplicationof2%minoxidilaftersystemiccorticosteroid
treatment augmented or helped to maintain hair growth in
patients who initially responded.
w13
Most experts reserve systemic corticosteroids for extensive or
rapidly progressive disease because of the known side effects
of prolonged systemic treatment with steroids and because
patients often relapse after stopping treatment.
w14
Dithranol
The aim of treatment with topical dithranol is to induce low
grade irritant scalp dermatitis (web appendix). Its therapeutic
role is supported by the observation of half-head regrowth in
some reports.
22w7 An uncontrolled trial of dithranol cream
(0.5-1%)appliedovernightinpatientswith“extensivealopecia
areata” (n=66) found that 25% of patients were eventually able
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CLINICAL REVIEWtostopwearingtheirwig(meandurationoftreatment28weeks;
range8-200weeks).
23Onestudy(n=32)reported“cosmetically
goodresults”in75%ofpatientswithlimiteddisease(including
ophiasis) and 25%of those with alopecia totalis after short term
applicationsof0.2-0.8%dithranolointment;half-headregrowth
was clearly demonstrated in these patients.
22 The combination
of 5% minoxidil and 0.5% dithranol cream overnight resulted
in11%ofpatientswith“extensive,treatmentresistant”alopecia
areata experiencing cosmetically acceptable regrowth after 24
weeks, which persisted in 80% of responders with continued
treatment.
24 Topical dithranol is thus a potentially effective
second line treatment for adults and children with persistent
disease.
Minoxidil
The evidence for the effectiveness of topical minoxidil is
conflicting. Some half-head studies have failed to report
significanttreatmenteffectsinalopeciatotalisanduniversalis
w15
w16 w17 and there appears to be no additional benefit of using 5%
minoxidil in conjunction with DPCP treatment.
w18 However,
two small placebo controlled trials have reported benefit in
patchy alopecia areata
25 26 and a small (n=32) randomised trial
of topical 2% minoxidil versus vehicle after a six week course
of oral corticosteroids showed that minoxidil seems to prevent
relapse in patients who responded to steroids (six of seven
minoxidil treated steroid responders compared with one of six
vehicle treated steroid responders).
w13 Minoxidil is frequently
used by experts as second line therapy or in conjunction with
other treatments.
w7
Others
A phase I/II randomised bilateral half-head comparison of
topical bexarotene 1% gel (n=42) identified a 26% response
rate in treated patients.
27 A randomised controlled trial of
aromatherapy (n=86) in which essential oils (thyme, rosemary,
lavender,cedarwood)weremassagedintothescalpdailyshowed
significant regrowth compared with the carrier oil alone
(P=0.008 for “improvement” v “no improvement”).
28 Oral
inosiplex (inosine pranobex) showed significantly better hair
re-growth compare with placebo in one small randomised
controlled trial.
29 All these results require confirmation in larger
controlled trials before they can be recommended.
Treatments in use that are not supported by
randomised controlled trials
Psoralen plus ultraviolet A photochemotherapy
(PUVA)
No controlled studies of PUVA therapy in alopecia areata have
been reported, so the reported “complete” regrowth rate of
48-53% from various studies is difficult to interpret.
w19 Other
studieshaveshownmuchlowerresponserates(6-13%)thatare
thought to be comparable with expected rates of spontaneous
remission.
w20 w21 High relapse rates in responders, uncertainty
about efficacy, inconvenience of multiple treatment sessions,
and concerns about PUVA induced skin carcinogenesis make
this a rarely used treatment in today’s practice.
Systemic immunosuppressants
Oral ciclosporin, methotrexate, and sulphasalazine all show
potentiallyencouragingresultsinuncontrolledstudieseitheras
monotherapy or in combination with oral corticosteroids.
w22 w23
w24 w25 Randomised controlled trials are needed to confirm these
provisional results.
Treatments with no effect in randomised
controlled trials
The biological agents alefacept,
w26 efalizumab,
w27 and
etanercept
w28 w29 are not effective at promoting hair regrowth in
alopecia areata. Photodynamic therapy is also ineffective.
w30
Topical prostaglandin analogues were ineffective in inducing
eyebroworeyelashregrowthinalopeciaareatadespiteefficacy
in healthy people.
w31 w32
Treatment in children
Generally treatment in children is similar to that in adults,
3
although intralesional corticosteroids are usually not well
tolerated and doctors are often reluctant to recommend
treatmentswithsubstantialorunknownsideeffectsforchildren.
Conclusion
For the entire, limited, repertoire of treatment options for
alopecia areata, researchers now need to focus on long term
outcomes and clinically meaningful end points (such as quality
of life measures) to identify the best strategies. Recognition of
outcomes from half-head trials of topical treatments, and
adoption of the standardised study methodology proposed by
theNationalAlopeciaAreataFoundationintheirinvestigational
assessment guidelines, should help to improve future study
design and appraisal of the literature.
30
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Tips for non-specialists
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Clarify the role of natural killer cells, natural killer cell activating ligands, and cytotoxic T-cells in alopecia areata
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Additional educational resources
Resources for healthcare professionals
Alopecia areata management (www.cks.nhs.uk/alopecia_areata)—UK National Health Service clinical knowledge summary for alopecia
areata
Alopecia areata (www.niams.nih.gov/Health_Info/Alopecia_Areata)—questions and answers from the US National Institute of Arthritis
and Musculoskeletal and Skin Diseases site
Information resources for patients
National Alopecia Areata Foundation (www.naaf.org)—clinical information and links to the US National Alopecia Areata Registry
Wigs for kids (www.wigsforkids.org)—US based charity that provides wigs for children with hair loss
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CLINICAL REVIEWFigures
Fig 1 Alopecia totalis treated with topical immunotherapy (2,3-diphenylcyclopropenone): (A) before treatment; (B) unilateral
hair regrowth after 15 weeks of unilateral treatment; (C) complete regrowth after 42 subsequent weeks of bilateral treatment.
Courtesy of R Happle, University of Marburg, Marburg, Germany
Fig 2 Clinical presentations of alopecia areata: (A) single patch; (B) multiple patches; (c) ophiasis pattern; (d) dermatoscopy
view of “exclamation mark” hairs (arrows; x30 magnification); note also monomorphic yellow dots, a common dermatoscopic
feature of alopecia areata
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